Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance

M. Radosevich, T. Burnouf

研究成果: 雜誌貢獻回顧型文獻同行評審

101 引文 斯高帕斯(Scopus)

摘要

Intravenous immunoglobulin G (IVIG) is now the leading product obtained by fractionation of human plasma. It is the standard replacement therapy in primary and acquired humoral deficiency, and is also used for immunomodulatory therapy in various autoimmune disorders and transplantation. Over the last 30 years, the production processes of IVIG have evolved dramatically, gradually resulting in the development of intact IgG preparations safe to administer intravenously, with normal half-life and effector functions, prepared at increased yield, and exhibiting higher pathogen safety. This article reviews the developments that have led to modern IVIG preparations, the current methods used for plasma collection and fractionation, the safety measures implemented to minimize the risks of pathogen transmission and the major quality control tests that are available for product development and as part of mandatory batch release procedures.
原文英語
頁(從 - 到)12-28
頁數17
期刊Vox Sanguinis
98
發行號1
DOIs
出版狀態已發佈 - 一月 2010
對外發佈Yes

ASJC Scopus subject areas

  • Hematology

指紋 深入研究「Intravenous immunoglobulin G: Trends in production methods, quality control and quality assurance」主題。共同形成了獨特的指紋。

引用此